Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
This study is a two-part study. Part A is double-blind, placebo-controlled, and will examine the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects. Part B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin, clopidogrel, apixaban or dabigatran.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A - LT3001 Drug Product | Experimental | Multiple doses of LT3001 administered by intravenous infusion |
|
| Part A - Placebo | Placebo Comparator | Multiple doses of Placebo administered by intravenous infusion |
|
| Part B - LT3001 and Aspirin | Experimental | Multiple doses of LT3001 and Aspirin administered |
|
| Part B - LT3001 and Clopidogrel | Experimental | Multiple doses of LT3001 and Clopidogrel administered |
|
| Part B - LT3001 and Apixaban | Experimental | Multiple doses of LT3001 and Apixaban administered |
|
| Part B - LT3001 and Dabigatran | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LT3001 drug product | Drug | Multiple doses of LT3001 drug product administered by intravenous infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Adverse Events | To evaluate the safety and tolerability of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran, as determined by the number and severity of adverse events collected from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B. | Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Activated Partial Thromboplastin Time (APTT) | Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, was assessed to evaluate the safety of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran from baseline up to 16 days post-dose. | 16 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mimi Yeh, PhD | Lumosa Phase 1 unit | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lumosa Phase 1 Unit | Cypress | California | 90630 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Part A - LT3001 Drug Product | Multiple doses of LT3001 administered by intravenous infusion LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion according to the study protocol. |
| FG001 | Part A - Placebo |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 11, 2021 | Jan 5, 2026 |
Not provided
Part A: parallel Part B: single group
Not provided
Not provided
Not provided
Multiple doses of LT3001 and Dabigatran administered
|
|
| Placebo | Drug | Multiple doses of Placebo administered by intravenous infusion |
|
|
| Aspirin | Drug | Loading and maintenance doses of Aspirin administered by oral |
|
|
| Clopidogrel | Drug | Loading and maintenance doses of Clopidogrel administered by oral |
|
|
| Apixaban | Drug | Multiple doses of Apixaban administered by oral |
|
|
| Dabigatran | Drug | Multiple doses of Dabigatran administered by oral |
|
|
| Number of Participants With Prolongation in Platelet Function Test |
The outcome measured the number of participants with prolongation in platelet function test results following administration of LT3001 alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran. Platelet function was assessed using collagen/epinephrine and collagen/ADP assays. Results were evaluated from baseline up to 16 days post-dose. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis. |
| 16 days |
| Plasma PK Parameters of LT3001 - Cmax | Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001. | Predose and post-dose time points up to 10 days after dosing |
| Plasma PK Parameters of LT3001 - Tmax | Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001. | 10 days |
| Plasma PK Parameters of LT3001 - AUC | Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001. | 10 days |
| Plasma PK Parameters of Aspirin - Cmax | Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered. | 8 days |
| Plasma PK Parameters of Aspirin - Tmax | Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered. | 8 days |
| Plasma PK Parameters of Aspirin - AUC | Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered. | 8 days |
| Plasma PK Parameters of Clopidogrel - Cmax | Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered. | 10 days |
| Plasma PK Parameters of Clopidogrel - Tmax | Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001). | 10 days |
| Plasma PK Parameters of Clopidogrel - AUC | Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered. | 10 days |
| Plasma PK Parameters of Apixaban - Cmax | Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered. | 8 days |
| Plasma PK Parameters of Apixaban - Tmax | Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered. | 8 days |
| Plasma PK Parameters of Apixaban - AUC | Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered. | 8 days |
| Plasma PK Parameters of Dabigatran - Cmax | Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran were administered. | 8 days |
| Plasma PK Parameters of Dabigatran - Tmax | Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001). | 8 days |
| Plasma PK Parameters of Dabigatran - AUC | Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001). | 8 days |
Multiple doses of Placebo administered by intravenous infusion Placebo: Multiple doses of Placebo administered by intravenous infusion according to the study protocol. |
| FG002 | Part B - LT3001 and Aspirin | Multiple doses of LT3001 administered by intravenous infusion in combination with oral aspirin administered at loading and maintenance doses according to the study protocol. |
| FG003 | Part B - LT3001 and Clopidogrel | Multiple doses of LT3001 administered by intravenous infusion in combination with oral Clopidogrel administered at loading and maintenance doses according to the study protocol. |
| FG004 | Part B - LT3001 and Apixaban | Multiple doses of LT3001 administered by intravenous infusion in combination with oral Apixaban administered at loading and maintenance doses according to the study protocol. |
| FG005 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 administered by intravenous infusion in combination with oral Dabigatran administered at loading and maintenance doses according to the study protocol. |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Part A - LT3001 Drug Product | Multiple doses of LT3001 administered by intravenous infusion LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion |
| BG001 | Part A - Placebo | Multiple doses of Placebo administered by intravenous infusion Placebo: Multiple doses of Placebo administered by intravenous infusion |
| BG002 | Part B - LT3001 and Aspirin | Multiple doses of LT3001 and Aspirin administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Aspirin: Loading and maintenance doses of Aspirin administered by oral |
| BG003 | Part B - LT3001 and Clopidogrel | Multiple doses of LT3001 and Clopidogrel administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Clopidogrel: Loading and maintenance doses of Clopidogrel administered by oral |
| BG004 | Part B - LT3001 and Apixaban | Multiple doses of LT3001 and Apixaban administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Apixaban: Multiple doses of Apixaban administered by oral |
| BG005 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral |
| BG006 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | A total of 13 subjects were enrolled in Part B Cohort 1, but only 12 subjects completed the study. | Count of Participants | Participants |
| |||||||||||||||
| Age, Continuous | Median | Full Range | year |
| |||||||||||||||
| Sex: Female, Male | A total of 13 subjects were enrolled in Part B cohort 1, but only 12 subjects completed the study. | Count of Participants | Participants |
| |||||||||||||||
| Race (NIH/OMB) | A total of 13 subjects were enrolled in Part B cohort 1, but only 12 subjects completed the study. | Count of Participants | Participants |
| |||||||||||||||
| Region of Enrollment | A total of 13 subjects were enrolled in Part B cohort 1, but only 12 subjects completed the study. | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Adverse Events | To evaluate the safety and tolerability of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran, as determined by the number and severity of adverse events collected from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B. | Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B. | Posted | Number | event | Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B. |
|
|
| |||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Activated Partial Thromboplastin Time (APTT) | Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, was assessed to evaluate the safety of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran from baseline up to 16 days post-dose. | Activated Partial Thromboplastin Time | Posted | Mean | Standard Deviation | second | 16 days |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Prolongation in Platelet Function Test | The outcome measured the number of participants with prolongation in platelet function test results following administration of LT3001 alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran. Platelet function was assessed using collagen/epinephrine and collagen/ADP assays. Results were evaluated from baseline up to 16 days post-dose. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis. | Prolongation in collagen/epinephrine or collagen/ADP. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis. | Posted | Count of Participants | Participants | No | 16 days |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of LT3001 - Cmax | Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001. | The pharmacokinetic analysis population included participants with sufficient plasma concentration data to estimate Cmax. Participants with missing or non-evaluable PK samples were excluded from the analysis. | Posted | Mean | Standard Deviation | ng/mL | Predose and post-dose time points up to 10 days after dosing |
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of LT3001 - Tmax | Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001. | Posted | Mean | Standard Deviation | hour | 10 days |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of LT3001 - AUC | Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001. | Posted | Mean | Standard Deviation | h*ng/mL | 10 days |
| |||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Aspirin - Cmax | Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered. | Posted | Mean | Standard Deviation | ng/mL | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Aspirin - Tmax | Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered. | Participants with Plasma concentrations of Aspirin at Day 5 | Posted | Mean | Standard Deviation | hour | 8 days |
|
| |||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Aspirin - AUC | Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered. | Posted | Mean | Standard Deviation | h*ng/mL | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Clopidogrel - Cmax | Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered. | Posted | Mean | Standard Deviation | ng/mL | 10 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Clopidogrel - Tmax | Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001). | Posted | Mean | Standard Deviation | hour | 10 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Clopidogrel - AUC | Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered. | Posted | Mean | Standard Deviation | h*ng/mL | 10 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Apixaban - Cmax | Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered. | Posted | Mean | Standard Deviation | ng/mL | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Apixaban - Tmax | Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered. | Posted | Mean | Standard Deviation | hour | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Apixaban - AUC | Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered. | Posted | Mean | Standard Deviation | h*ng/mL | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Dabigatran - Cmax | Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran were administered. | Posted | Mean | Standard Deviation | ng/mL | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Dabigatran - Tmax | Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001). | Posted | Mean | Standard Deviation | hour | 8 days |
|
| ||||||||||||||||||||||||||||||||||||||||||
| Secondary | Plasma PK Parameters of Dabigatran - AUC | Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001). | Posted | Mean | Standard Deviation | h*ng/mL | 8 days |
|
|
Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.
All-cause mortality, serious adverse events, and other (non-serious) adverse events were monitored during the specified adverse event reporting period.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Part A - LT3001 Drug Product | Multiple doses of LT3001 administered by intravenous infusion LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion | 0 | 12 | 0 | 12 | 3 | 12 |
| EG001 | Part A - Placebo | Multiple doses of Placebo administered by intravenous infusion Placebo: Multiple doses of Placebo administered by intravenous infusion | 0 | 4 | 0 | 4 | 0 | 4 |
| EG002 | Part B - LT3001 and Aspirin | Multiple doses of LT3001 and Aspirin administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Aspirin: Loading and maintenance doses of Aspirin administered by oral | 0 | 12 | 0 | 12 | 2 | 12 |
| EG003 | Part B - LT3001 and Clopidogrel | Multiple doses of LT3001 and Clopidogrel administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Clopidogrel: Loading and maintenance doses of Clopidogrel administered by oral | 0 | 12 | 0 | 12 | 2 | 12 |
| EG004 | Part B - LT3001 and Apixaban | Multiple doses of LT3001 and Apixaban administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Apixaban: Multiple doses of Apixaban administered by oral | 0 | 12 | 0 | 12 | 2 | 12 |
| EG005 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral | 0 | 12 | 0 | 12 | 1 | 12 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Menstruation irregular | Endocrine disorders | MedDRA | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Oral herpes | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Thoracic outlet syndrome | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Contusion | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Thrombophlebitis superficial | Vascular disorders | MedDRA | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Contact of Clinical Trials | Lumosa | 886-2-26557918 | kevin_hsiao@lumosa.com.tw |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Aug 18, 2021 | Jan 22, 2026 | SAP_001.pdf |
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001241 | Aspirin |
| D000077144 | Clopidogrel |
| C522181 | apixaban |
| D000069604 | Dabigatran |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D013988 | Ticlopidine |
| D058924 | Thienopyridines |
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D001562 | Benzimidazoles |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Part B - LT3001 and Clopidogrel |
Multiple doses of LT3001 and Clopidogrel administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Clopidogrel: Loading and maintenance doses of Clopidogrel administered by oral |
| OG004 | Part B - LT3001 and Apixaban | Multiple doses of LT3001 and Apixaban administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Apixaban: Multiple doses of Apixaban administered by oral |
| OG005 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral |
|
|
Multiple doses of LT3001 and Clopidogrel administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Clopidogrel: Loading and maintenance doses of Clopidogrel administered by oral |
| OG003 | Part B - LT3001 and Apixaban | Multiple doses of LT3001 and Apixaban administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Apixaban: Multiple doses of Apixaban administered by oral |
| OG004 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral |
|
|
| OG003 | Part B - LT3001 and Apixaban | Multiple doses of LT3001 and Apixaban administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Apixaban: Multiple doses of Apixaban administered by oral |
| OG004 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral |
|
|
Multiple doses of LT3001 and Apixaban administered
LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion
Apixaban: Multiple doses of Apixaban administered by oral
| OG004 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral |
|
|
Multiple doses of LT3001 and Apixaban administered
LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion
Apixaban: Multiple doses of Apixaban administered by oral
| OG004 | Part B - LT3001 and Dabigatran | Multiple doses of LT3001 and Dabigatran administered LT3001 drug product: Multiple doses of LT3001 drug product administered by intravenous infusion Dabigatran: Multiple doses of Dabigatran administered by oral |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|